ESC Premium Access

Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI)

Congress Presentation

About the speaker

Doctor Genmin Lu

Portola Pharmaceuticals Inc, South San Francisco (United States of America)
0 follower

9 more presentations in this session

Dyslipidemia associated oxidised ldl induces platelet hyperactivity through a cd36-dependent activation of pde3a

Speaker: Doctor M. Berger (Aachen, DE)

Thumbnail

Alterations in clot architecture associated with low fibrinolytic potential in acute myocardial infarction

Speaker: Doctor N. Spinthakis (Exeter, GB)

Thumbnail

Low- level confocal dual- pulse electrohydraulic shock wave therapy accompanied by tissue plasminogen activator and microbubbles administration for intracranial arterial recanalization

Speaker: Doctor H. Mehrad (Tabriz, IR)

Thumbnail

JNJ-9375, a novel exosite 1 thrombin inhibitor does not increase bleeding in a spontaneous gastrointestinal (GI) bleeding model in mice with a mutation of the Adenomatous polyposis coli (Apc) gene

Speaker: Doctor M. Chintala (Spring House, US)

Thumbnail

Pharmacological inhibition of S6K1 facilitates platelet activation by enhancing Akt phosphorylation

Speaker: Doctor W. Gao (Shanghai, CN)

Thumbnail

Access the full session

Platelets, haemostasis and coagulation

Speakers: Doctor G. Lu, Doctor M. Berger, Doctor N. Spinthakis, Doctor H. Mehrad, Doctor M. Chintala...
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb